1Kantoff P W,Halabi S,Conaway M,et al.Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer:results of the cancer and leukemia group B 9182 study[J].J Clin Oncol,1999,17:2506-2513.
2Tannock I F,Osoba D,Stockler M R,et al.Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer:a canadian randomized trial with palliative end points[J].J Clin Oncol,1996,14:1756-1764.
3Beer T M,Pierce W C,Lowe B A,et al.Phase Ⅱ study of weekly docetaxel in symptomatic androgen-independent prostate cancer[J].Ann Oncol,2001,12:1273-1279.
4Picus J,Schultz M.Docetaxel (Taxotere) as monotherapy in the treatmentof hormone-refractory prostate cancer:preliminary results[J].Semin Oncol,1999,26(5 Suppl 17):14-18.
5Petrylak D P,Tangen C M,Hussain M H,et al.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostatecancer[J].N EnglJ Med,2004,351:1513-1520.
6Tannock I F,de Wit R,Berry W R,et al.Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer[J].N Engl J Med,2004,351:1502-1512.
7Bubley G J,Carducci M,Dahut W,et al.Eligibility and response guidelines for phase Ⅱ clinical trials in androgenindependent prostate cancer:recommendations from the Prostate-Specific Antigen Working Group[J].J Clin Oncol,1999,17:3461-3467.
8Roth B J,Yeap B Y,Wilding G,et al.Taxel in advanced hormone-refractory carcinoma of the prostate:a phase Ⅱ trial of the Eastern Cooperative Oncology Group[J].Cancer,1993,72:2457-2460.
9Trivedi C,Redman B,Flaherty L E,et al.Weekly 1-hour infusion of paclitaxel:clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma[J].Cancer,2000,89:431-436.
10Picus J,Schultz M.Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer:preliminary results[J].Semin Oncol,1999,26:14-18.
